Adaptin Bio (APTN) Change in Accured Expenses (2023 - 2026)

Adaptin Bio has disclosed Change in Accured Expenses across 4 years of filings, most recently posting -$42777.0 for Q2 2026.

• In Q2 2026, Change in Accured Expenses rose 83.55% year-over-year to -$42777.0; the TTM figure through Jun 2026 stood at $288933.0 (up 217.61% YoY), while the FY2025 annual figure was -$453445.0, down 153.26% from the prior year.
• Change in Accured Expenses came in at -$42777.0 for Q2 2026 at Adaptin Bio, down from $256901.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $636596.0 in Q2 2024 to a low of -$268226.0 in Q1 2025.
• Average Change in Accured Expenses over 4 years is $53049.8, with a median of $820.0 recorded in 2025.
• Year-over-year, Change in Accured Expenses jumped 811.22% in 2024 and plunged 295.27% in 2025.
• Over 4 years, Change in Accured Expenses stood at -$28442.0 in 2023, then jumped by 811.22% to $202286.0 in 2024, then plunged by 63.42% to $73989.0 in 2025, then plunged by 157.82% to -$42777.0 in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$42777.0 in Q2 2026, $256901.0 in Q1 2026, and $73989.0 in Q4 2025.